Quince Therapeutics, a late-stage biotechnology company focused on treating rare diseases, provided a pipeline update and financial results for the third quarter of 2024. The company highlighted progress in its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T). As of the announcement date, 32 patients with A-T were enrolled across U.S., U.K., and EU clinical sites. With most planned NEAT study sites active, the company anticipates continued enrollment momentum. Quince aims to complete enrollment by the second quarter of 2025, with topline results expected in the fourth quarter of 2025.
Quince Therapeutics concentrates on harnessing a patient’s biology to treat rare conditions. Its lead candidate, EryDex, is developing for A-T, Duchenne muscular dystrophy (DMD), and other potential indications. The company leverages its proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology, which it intends to expand to treat additional rare diseases.
The company’s forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, address anticipated developments related to EryDex, including its potential to treat various diseases and the expansion of the AIDE technology. These statements reflect current expectations but are subject to inherent uncertainties and risks. Factors that could influence actual outcomes include but are not limited to, risks detailed in the company’s SEC filings, including its Quarterly Report on Form 10-Q. These forward-looking projections are current as of the announcement date, and Quince has no obligation to update this information unless legally required. More details about Quince Therapeutics and its latest news can be found on their website and social media channels.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
